中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2014年
6期
1042-1043
,共2页
沙利度胺%肝癌%奥沙利铂%5-氟尿嘧啶%亚叶酸钙%临床疗效
沙利度胺%肝癌%奧沙利鉑%5-氟尿嘧啶%亞葉痠鈣%臨床療效
사리도알%간암%오사리박%5-불뇨밀정%아협산개%림상료효
Thalidomide%Liver cancer%Oxaliplatin%5-FU%Leucovorin%Clinical efficacy
目的：探讨沙利度胺联合FOLFOX4方案治疗晚期肝癌的临床疗效。方法：回顾性分析我院2011年6月~2013年7月收治的70例晚期肝癌患者的资料,随机分为观察组和对照组,各35例,两组患者均采用奥沙利铂(L-OHP)联合5-氟尿嘧啶(5-FU)/亚叶酸钙(CF)组成的FOLFOX4化学治疗(化疗)方案,观察组患者同期行沙利度胺联合化疗,1个月后确定疗效,比较两组患者近期缓解率、化疗后毒副作用以及血清血管内皮生长因子(VEGF)变化情况。结果：观察组患者近期缓解率明显高于对照组,比较差异有统计学意义(P<0.05)。两组患者化疗后VEGF含量均下降,观察组患者下降更为明显,比较差异有统计学意义(P<0.05)。观察组患者嗜睡、乏力、头晕、皮疹等症状发生率高于对照组,比较差异有统计学意义(P<0.05)。结论：沙利度胺联合FOLFOX4方案治疗晚期肝癌,能提高患者疾病控制率,降低血清VEGF水平,毒副作用可耐受,值得在临床推广。
目的：探討沙利度胺聯閤FOLFOX4方案治療晚期肝癌的臨床療效。方法：迴顧性分析我院2011年6月~2013年7月收治的70例晚期肝癌患者的資料,隨機分為觀察組和對照組,各35例,兩組患者均採用奧沙利鉑(L-OHP)聯閤5-氟尿嘧啶(5-FU)/亞葉痠鈣(CF)組成的FOLFOX4化學治療(化療)方案,觀察組患者同期行沙利度胺聯閤化療,1箇月後確定療效,比較兩組患者近期緩解率、化療後毒副作用以及血清血管內皮生長因子(VEGF)變化情況。結果：觀察組患者近期緩解率明顯高于對照組,比較差異有統計學意義(P<0.05)。兩組患者化療後VEGF含量均下降,觀察組患者下降更為明顯,比較差異有統計學意義(P<0.05)。觀察組患者嗜睡、乏力、頭暈、皮疹等癥狀髮生率高于對照組,比較差異有統計學意義(P<0.05)。結論：沙利度胺聯閤FOLFOX4方案治療晚期肝癌,能提高患者疾病控製率,降低血清VEGF水平,毒副作用可耐受,值得在臨床推廣。
목적：탐토사리도알연합FOLFOX4방안치료만기간암적림상료효。방법：회고성분석아원2011년6월~2013년7월수치적70례만기간암환자적자료,수궤분위관찰조화대조조,각35례,량조환자균채용오사리박(L-OHP)연합5-불뇨밀정(5-FU)/아협산개(CF)조성적FOLFOX4화학치료(화료)방안,관찰조환자동기행사리도알연합화료,1개월후학정료효,비교량조환자근기완해솔、화료후독부작용이급혈청혈관내피생장인자(VEGF)변화정황。결과：관찰조환자근기완해솔명현고우대조조,비교차이유통계학의의(P<0.05)。량조환자화료후VEGF함량균하강,관찰조환자하강경위명현,비교차이유통계학의의(P<0.05)。관찰조환자기수、핍력、두훈、피진등증상발생솔고우대조조,비교차이유통계학의의(P<0.05)。결론：사리도알연합FOLFOX4방안치료만기간암,능제고환자질병공제솔,강저혈청VEGF수평,독부작용가내수,치득재림상추엄。
To investigate the clinical efficacy of thalidomide combined with FOLFOX4 treatment of advanced liver cancer.Methods:A retrospective analysis was performed on 70 patients with advanced liver cancer in our hospital in June 2011 ~July 2013.All of the patients were randomly divided into the observation group and the control group,and each group contains 35 cases respectively.Patients in Both of the two groups were treated with oxaliplatin (L-OHP) combined with 5-fluorouracil (5-FU)/leucovorin (CF) FOLFOX4 chemotherapy regimen while patients of the observation group were treated with thalidomide in combination with FOLFOX4 chemotherapy.Clinical efficacy was evaluated and the recently remission rate,toxic effects and serum vascular endothelial growth factor (VEGF) changes between the two groups were compared one month later.Results:The recently response rate was significantly higher in patients of the observation group than the control group and the difference was statistically significant (P<0.05).The decrease of VEGF levels was observed in both two groups after chemotherapy and more significant in the observation group (P<0.05).The incidence of somno lence,fatigue,dizziness,skin rashes and other symptoms in the observation group were higher and the difference was statistically significant (P<0.05).Conclusion:Thalidomide combined with FOLFOX4 treatment of advanced liver cancer can improve chemotherapy response rate and lower the serum VEGF levels.The side effects can be tolerated.
